Indeed, in SCID mice bearing s.c. melanoma xenografts, we found that the AZD6244–TRAIL association exerted a significant anti-tumor activity, compared with single treatments, in a TRAIL-resistant tumor. This evidence concerns the gene TNFSF10 and neoplasm.